The incidence of migraine is higher among women than men and peaks during the 
reproductive years, when contraceptive medication use is common. Atogepant, a 
potent, selective antagonist of the calcitonin gene-related peptide receptor-in 
development for migraine prevention-is thus likely to be used by women taking 
oral contraceptives. This phase 1, open-label, single-center, 2-period, 
fixed-sequence study examined the effect of multiple-dose atogepant 60 mg once 
daily on the single-dose pharmacokinetics of a combination oral contraceptive, 
ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg (EE/LNG), in healthy 
postmenopausal or oophorectomized women. For participants in period 1, a single 
dose of EE/LNG was followed by a 7-day washout. In period 2, atogepant was given 
once daily on days 1-17; an oral dose of EE/LNG was coadministered with 
atogepant on day 14. Plasma pharmacokinetic parameters for EE and LNG were 
assessed following administration with and without atogepant. Twenty-six 
participants aged 45-64 years enrolled; 22 completed the study in accordance 
with the protocol. The area under the concentration-time curve extrapolated to 
infinity (AUC0-∞ ) of LNG was increased by 19% when administered with atogepant. 
Coadministration of atogepant and a single dose of EE/LNG did not substantially 
alter the pharmacokinetics of EE; the ∼19% increase in plasma AUC0-∞ of LNG is 
not anticipated to be clinically significant. Overall, atogepant alone and in 
combination with EE/LNG was generally well tolerated, with no new safety signals 
identified.